Related references
Note: Only part of the references are listed.A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank
Jon B. Toledo et al.
ALZHEIMERS & DEMENTIA (2014)
Plasma Apolipoprotein A1 as a Biomarker for Parkinson Disease
Judy K. Qiang et al.
ANNALS OF NEUROLOGY (2013)
Gene-diet interactions on plasma lipid levels in the Inuit population
Iwona Rudkowska et al.
BRITISH JOURNAL OF NUTRITION (2013)
Genetic Polymorphisms in the APOA1 Gene and their Relationship with Serum HDL Cholesterol Levels
Fatemeh Bandarian et al.
LIPIDS (2013)
Discontinuation of statin therapy associates with Parkinson disease A population-based study
Yen-Chieh Lee et al.
NEUROLOGY (2013)
Prospective Study of Statin Use and Risk of Parkinson Disease
Xiang Gao et al.
ARCHIVES OF NEUROLOGY (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects
Chera L. Maarouf et al.
NEUROLOGICAL RESEARCH (2012)
Plasma Epidermal Growth Factor Levels Predict Cognitive Decline in Parkinson Disease
Alice S. Chen-Plotkin et al.
ANNALS OF NEUROLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study (vol 10, pg 230, 2011)
B. Mollenhauer et al.
LANCET NEUROLOGY (2011)
Apolipoprotein A1/C3/A5 haplotypes and serum lipid levels
Rui-Xing Yin et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Does vigorous exercise have a neuroprotective effect in Parkinson disease?
J. Eric Ahlskog
NEUROLOGY (2011)
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
Brit Mollenhauer et al.
LANCET NEUROLOGY (2011)
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease
Zhen Hong et al.
BRAIN (2010)
Apolipoprotein A-I Deficiency Increases Cerebral Amyloid Angiopathy and Cognitive Deficits in APP/PS1ΔE9 Mice
Iliya Lefterov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease
Terry L. Lewis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP43 inclusions
Vivianna M. Van Deerlin et al.
NATURE GENETICS (2010)
Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries
Allison Wright Willis et al.
NEUROEPIDEMIOLOGY (2010)
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease
Min Shi et al.
NEUROSCIENCE LETTERS (2010)
An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis
G. Koutsis et al.
MULTIPLE SCLEROSIS (2009)
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Javier Simon-Sanchez et al.
NATURE GENETICS (2009)
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
Michael A. Schwarzschild et al.
ARCHIVES OF NEUROLOGY (2008)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Apolipoprotein A1 genotype affects the change in high density lipoprotein cholesterol subfractions with exercise training
G Ruaño et al.
ATHEROSCLEROSIS (2006)
APOA1 polymorphism influences risk for early-onset nonfamiliar AD
H Vollbach et al.
ANNALS OF NEUROLOGY (2005)
Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake
H Checkoway et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2002)